ClinConnect ClinConnect Logo
Search / Trial NCT05313412

Clinical Evaluation of Two Silicone Hydrogel Contact Lenses

Launched by COOPERVISION, INC. · Apr 1, 2022

Trial Information

Current as of July 25, 2025

Completed

Keywords

ClinConnect Summary

This is a double-masked, randomized, bilateral crossover study to compare the short-term clinical performance of two silicone hydrogel soft contact lenses. Each lens type is worn for approximately six hours on separate study days, in random sequence.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. They are aged between 18 and 40 years.
  • 2. They understand their rights as a research subject and are willing and able to sign a Statement of Informed Consent.
  • 3. They are willing and able to follow the protocol.
  • 4. They have successfully worn contact lenses within six months of starting the study.
  • 5. They can be satisfactorily fitted with the study contact lenses.
  • 6. They have a contact lens spherical prescription between -0.25 to - 6.00D (inclusive) based on the ocular refraction.
  • 7. They have a spectacle cylindrical correction of -0.75D or less in each eye based on the ocular refraction.
  • 8. They own and habitually wear single vision spectacles.
  • 9. They can attain at least 0.20 logMAR distance high contrast visual acuity in each eye, with the study lenses.
  • 10. They agree not to participate in other clinical research while enrolled on this study.
  • Exclusion Criteria:
  • 1. They have an ocular disorder which would normally contraindicate contact lens wear.
  • 2. They have a systemic disorder which would normally contraindicate contact lens wear.
  • 3. They are using any topical medication such as eye drops or ointment.
  • 4. They are aphakic.
  • 5. They have had corneal refractive surgery.
  • 6. They have any corneal distortion resulting from previous hard or rigid lens wear or have keratoconus.
  • 7. They are pregnant or breastfeeding.
  • 8. They have any ocular abnormality which would, in the opinion of the investigator, normally contraindicate contact lens wear or pose a risk to study personnel; or they have any immunosuppressive disease (eg HIV) or a history of anaphylaxis or severe allergic reaction.
  • 9. They have grade 3 or greater of any of the following ocular surface signs: corneal oedema, corneal vascularisation, corneal staining, tarsal conjunctival changes or any other abnormality, which would normally contraindicate contact lens wear.
  • 10. They have taken part in any other clinical trial or research, within two weeks prior to starting this study, which may impact on this particular work.

About Coopervision, Inc.

CooperVision, Inc. is a global leader in the contact lens industry, dedicated to advancing the science of vision care through innovative products and clinical research. With a commitment to enhancing the quality of life for millions of wearers worldwide, the company specializes in developing a diverse range of contact lenses, including those for myopia control, astigmatism, and presbyopia. CooperVision actively engages in clinical trials to ensure the safety, efficacy, and comfort of its products, while also contributing to the broader understanding of eye health and vision correction. By fostering partnerships with healthcare professionals and researchers, CooperVision aims to drive advancements in vision care and provide exceptional solutions that meet the evolving needs of eye care practitioners and their patients.

Locations

Manchester, , United Kingdom

Patients applied

0 patients applied

Trial Officials

Philip Morgan, PhD,MCOptom

Principal Investigator

Eurolens Research

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials